Willem J. Remme
#148,575
Most Influential Person Now
Willem J. Remme's AcademicInfluence.com Rankings
Willem J. Remmemedical Degrees
Medical
#2830
World Rank
#3269
Historical Rank
Cardiology
#270
World Rank
#276
Historical Rank
Download Badge
Medical Physics
Willem J. Remme's Degrees
- Bachelors Physics University of Amsterdam
- Masters Physics University of Amsterdam
- PhD Physics University of Amsterdam
Why Is Willem J. Remme Influential?
(Suggest an Edit or Addition)Willem J. Remme's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. (1999) (7676)
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005) (5789)
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure (2000) (5314)
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction (2003) (3033)
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial (2003) (1756)
- Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. (2003) (1659)
- Guidelines for the diagnosis and treatment of chronic heart failure. (2001) (1628)
- EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION (2003) (983)
- Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. (1986) (519)
- Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology (2002) (482)
- Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. (2000) (375)
- Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. (1986) (363)
- The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction (2004) (355)
- The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. (2001) (267)
- Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. (2005) (265)
- The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. (2006) (227)
- [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. (2005) (214)
- Reproducibility and relation to mean heart rate of heart rate variability in normal subjects and in patients with congestive heart failure secondary to coronary artery disease. (1991) (209)
- Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. (2005) (191)
- [Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)]. (2005) (159)
- The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN) (2004) (146)
- The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. (2005) (137)
- Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report (2002) (134)
- Public awareness of heart failure in Europe: first results from SHAPE. (2005) (123)
- Effects of bisoprolol on heart rate variability in heart failure. (1996) (119)
- Beta-blocking agents in heart failure. Should they be used and how? (1996) (112)
- The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). (1998) (106)
- Should beta‐blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET (2007) (104)
- Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. (2008) (93)
- Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET (2002) (93)
- The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. (1997) (91)
- Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial (2007) (81)
- Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. (2010) (81)
- Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial (2010) (80)
- Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. (2005) (78)
- A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). (2006) (74)
- Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN) (2004) (72)
- Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005) The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology (2005) (70)
- Guidelines for the diagnosis and treatment of chronic heart failure Task Force for the Diagnosis and Treatment of Chronic Heart Failure , European Society of Cardiology : (2001) (68)
- Pharmacological Modulation of Cardiovascular Remodeling: A Guide to Heart Failure Therapy (2003) (65)
- Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study (2006) (64)
- The sympathetic nervous system and ischaemic heart disease. (1998) (63)
- The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. (2009) (62)
- Effects of pacing-induced myocardial ischemia on hypoxanthine efflux from the human heart. (1977) (62)
- The safety of amiodarone in patients with heart failure. (2007) (59)
- Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). (2007) (58)
- Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. (2007) (56)
- The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. (2007) (52)
- Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. (2006) (48)
- ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial (2007) (48)
- A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals (2011) (47)
- Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure (2004) (46)
- Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. (1991) (45)
- Effect of carvedilol and metoprolol on the mode of death in patients with heart failure (2007) (44)
- The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)—Rationale and Design (2004) (44)
- Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. (1994) (42)
- Overview of the relationship between ischemia and congestive heart failure (2000) (42)
- Acute hemodynamic and antiischemic effects of intravenous amiodarone. (1985) (41)
- Inodilator therapy for heart failure. Early, late, or not at all? (1993) (38)
- Temporal relation of changes in regional coronary flow and myocardial lactate and nucleoside metabolism during pacing-induced ischemia. (1986) (38)
- Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. (1996) (38)
- Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure (2008) (36)
- Myocardial nucleoside and carbohydrate metabolism and hemodynamics during partial occlusion and reperfusion of pig coronary artery. (1977) (36)
- Exchange of β‐blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial) (2004) (36)
- Guidelines for the diagnosis and treatment of Chronic Heart Failure : full (2005) (36)
- Clinical Trials Update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY (2007) (35)
- ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: Pertinent (2007) (35)
- Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. (1994) (34)
- Low vitamin B6 status in patients with acute myocardial infarction. (1989) (32)
- Long term improvement in global left ventricular function after early thrombolytic treatment in acute myocardial infarction. Report of a randomised multicentre trial of intracoronary streptokinase in acute myocardial infarction. (1986) (32)
- Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. (1994) (31)
- Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease. (2013) (31)
- Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA? (2009) (30)
- Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. (1999) (29)
- Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. (2007) (28)
- Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor–Based Regimens: An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials (2010) (28)
- Acute effects of intravenous amiodarone in patients with complex ventricular dysrhythmias (1982) (24)
- Towards the better treatment of heart failure. (1998) (23)
- Therapeutic strategies and neurohormonal control in heart failure. (1994) (23)
- Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris. (1991) (22)
- Long-term efficacy and safety of Pimobendan in moderate heart failure: A double-blind parallel 6-month comparison with enalapril (1994) (22)
- Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study. (2009) (22)
- Anti-ischaemic efficacy of L-propionylcarnitine--a promising novel metabolic approach to ischaemia? (1996) (21)
- PERindopril—Function of the Endothelium in Coronary Artery Disease Trial: The PERFECT Study—Sub Study of EUROPA: Rationale and Design (2002) (21)
- Should ACE Inhibition Always be First-Line Therapy in Heart Failure? Lessons from the CARMEN Study (2003) (21)
- Cardiovascular and antiarrhythmic effects of aprindine (AC1802) during partial occlusion of a coronary artery in the pig. (1977) (20)
- Which Beta-Blocker is Most Effective in Heart Failure? (2010) (20)
- A non-invasive selective assessment of type I fibre mitochondrial function using 31P NMR spectroscopy. Evidence for impaired oxidative phosphorylation rate in skeletal muscle in patients with chronic heart failure. (1998) (20)
- Increasing Awareness and Perception of Heart Failure in Europe and Improving Care—Rationale and Design of the SHAPE Study (2004) (20)
- Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. (2007) (20)
- Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. (2015) (20)
- When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches (2012) (19)
- Prevention of worsening heart failure: future focus. (1998) (19)
- Hemodynamic Effects of Intravenous Pimobendan in Patients with Left Ventricular Dysfunction (1989) (18)
- Amiodarone. Haemodynamic profile during intravenous administration and effect on pacing-induced ischaemia in man. (1985) (18)
- Antiarrhythmic, metabolic and hemodynamic effects of Org 6001 (3alpha-amino-5alpha-androstan-2beta-ol-17-one-hydrochloride) after coronary flow reduction in pigs. (1978) (18)
- Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial (2007) (17)
- Effects of intracoronary thrombolysis on global left ventricular function assessed by an automated edge detection technique. (1986) (17)
- Treatment guidelines in heart failure. (1998) (17)
- Neurohormonal modulation in heart failure: ACE inhibition and beyond. (1995) (16)
- Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarction. (1999) (16)
- Inotropic agents for heart failure: what if digoxin increases mortality? (1994) (16)
- Congestive Heart Failure: Pathophysiology and Medical Treatment (1986) (14)
- Preload-dependent hemodynamic effects of milrinone in moderate heart failure. (1992) (14)
- Effect of ACE inhibition on neurohormones. (1998) (14)
- Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties. (1985) (13)
- Secondary Prevention of Coronary Artery Disease and the Choice of the ACE Inhibitor Why EUROPA and not PEACE (2007) (13)
- Renal Hemodynamic Effects in Patients with Moderate to Severe Heart Failure during Chronic Treatment with Trandolapril (1998) (12)
- Clinical Trials Update AHA Congress 2010 (2011) (12)
- Medical Misinformation. (2019) (12)
- Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model (2016) (12)
- Anti-ischaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects. (1995) (11)
- A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET) (2004) (11)
- Bradykinin-Mediated Cardiovascular Protective Actions of ACE Inhibitors (2012) (11)
- Acute myocardial ischaemia induces cardiac carnitine release in man. (1997) (11)
- EUROPA substudies, confirmation of pathophysiological concepts (1998) (11)
- Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II) (2011) (10)
- Years‐needed‐to‐treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials (2009) (10)
- Hemodynamic Effect of Nifedipine (Adalat) in Patients Catheterized for Coronary Artery Disease (1975) (10)
- Neurohumoral activation during acute myocardial ischaemia. Effects of ACE inhibition. (1990) (9)
- Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol. (1992) (9)
- Myocardial substrate utilization and hemodynamics following repeated coronary flow reduction in pigs (1979) (9)
- Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. (2009) (9)
- Filling the gap between guidelines and clinical practice in heart failure treatment — Still a far cry from reality (2007) (9)
- Continuous determination of regional myocardial blood flow with intracoronary krypton-81m in coronary artery disease. (1985) (9)
- 835-2 Carvedilol better protects against vascular events than metoprolol in heart failure: Results from COMET (2004) (8)
- Medical Misinformation: Vet the Message! (2019) (8)
- Treatment of congestive heart failure. Has the time come for decreased complexity? (1999) (8)
- Acute antiischaemic properties of high dosages of intravenous diltiazem in humans in relation to its coronary and systemic haemodynamic effects. (1987) (8)
- Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA. (2015) (8)
- Vasodilator therapy without converting-enzyme inhibition in congestive heart failure—Usefulness and limitations (1989) (7)
- Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery disease. (1989) (7)
- Sinus node inhibitors (1991) (7)
- Additional antiischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy (1995) (7)
- Antiarrhythmic and hemodynamic effects of an aminosteroid (Org 3001) in the digitalized dog. (1976) (7)
- Replacement of angiotensin converting enzyme inhibition by carvedilol results in long-term reversed left ventricular remodeling in mild heart failure and is well tolerated: Results of the CARMEN (Carvedilol aceinhibitor remodeling in mild heart failure evaluation) study (2003) (7)
- Dose related coronary and systemic haemodynamic effects of intravenous bepridil in patients with coronary artery disease. (1987) (6)
- Present treatment options in congestive heart failure (1998) (6)
- Heart failure management : why evidence does not influence clinical practice (2000) (6)
- A Statement on Ethics from the HEART Group (2008) (6)
- Positive Inotropes—A New Horizon or Still a Dead End? (2001) (6)
- Improved assessment of lactate production during pacing induced ischemia (1981) (6)
- 184 Effect of long-term treatment with carvedilol compared to metoprolol on heart failure morbidity and diabetes in COMET (2004) (5)
- Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. (1994) (5)
- Continuous myocardial bloodflow distribution imaging in man with krypton 81 m intracoronary : Correlation with myocardial lactate metabolism during single and repetitive periods of myocardial ischemia (1982) (5)
- Dopaminergic Agents in Heart Failure: Rebirth of An Old Concept (2001) (5)
- A statement on ethics from the HEART Group (2009) (5)
- Hypotension After First-Dose ACE Inhibitor Administration in Heart Failure—Should Doctors Stop Worrying? (2001) (5)
- muscle in patients with chronic heart failure (1998) (4)
- Myocardial arteriovenous difference in carbohydrates, purine nucleosides and electrolytes following occlusion and release of pig coronary artery☆ (1976) (4)
- Positive inotropic therapy: dead end or new horizon? (1996) (4)
- Lactate extraction pattern during repeated ischemia in the human heart (1981) (4)
- 835-3 Beta-blocker dose does not influence the beneficial effects of carvedilol compared to metroprolol in the patients with heart failure: Results from the carvedilol or Metoprolol European Trial (COMET) (2004) (4)
- Drug-induced heart failure. (1999) (4)
- Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first? (2007) (4)
- Cardiovascular Drugs and Therapy Celebrates its 25th Year of Publication with a New Section: Education in Cardiovascular Therapy (2011) (4)
- Hemodynamic profile of amiodarone during acute and long-term administration in patients with ventricular dysfunction. (1990) (4)
- Hemodynamic tolerability and anti-ischemic efficacy of high dose intravenous diltiazem in patients with normal versus impaired ventricular function. (1993) (4)
- Do patients necessarily have to start with an angiotension converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE Inhibitor Remodeling Mild CHF Evaluation) study (2003) (4)
- Clinical profile and outcome of anaemic patients with chronic heart failure in the COMET trial (2004) (4)
- Medical Misinformation: Vet the Message! (2019) (4)
- P1027 SHAPE (study of heart failure awareness and perception in Europe): a pan-European general public survey on awareness and perception of the clinical, social and economic importance of heart failure (2003) (3)
- Beta-blockade as First-line Therapy in the Elderly Heart Failure Patient—the Proper Approach or Asking for Trouble? (2008) (3)
- Fundamental Validity and Clinical Usefulness of Myocardial Lactate Balance During Ischaemia A comparison with Other Biochemical Markers (1980) (3)
- 835-4 Comparison of the effects of metoprolol and carvedilol on symptoms, well-being, and quality-adjusted life-years: A description of the patient-journey in COMET (2004) (3)
- Neurohumoral Response to Carmoxirole, a Selective Dopamine (D2) Receptor Agonist, in Patients with Chronic Moderate Heart Failure (2004) (3)
- Clinical Trials Update from the European Society of Cardiology Congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE (2009) (3)
- Visualization of Myocardial Blood-Flow Changes with Intracoronary 81mKr (1985) (3)
- Cardiovascular effects of an antiarrhythmic aminosteroid ORG 6001 in the anesthetized pig. (1976) (2)
- 958-96 Enalapril Does not Affect Ischemia During Short-term Treatment in Stable Angina Pectoris Irrespective of Its Effect on Blood Pressure (1995) (2)
- 3643 Does baseline heart rate determine the effect of carvedilol on ventricular remodelling in heart failure? Results of the CARMEN trial (2003) (2)
- Pathophysiology and therapy of heart failure, new insights and developments. Part II. Cardiac and peripheral alterations during progressive heart failure. (1993) (2)
- Acute Hemodynamic and Neurohumoral Profile of Dilevalol in Hypertensive Patients with Ischemic Heart Disease (1993) (2)
- Contrasting preload-dependent hemodynamic and neurohumoral effects of isomazole, a partial phosphodiesterase inhibitor and calcium sensitizer. (1997) (2)
- 1001-26 Exchange of beta-blocking therapy in heart failure patients. Experiences from the post study phase of COMET (the carvedilol or metoprolol European trial) (2004) (2)
- 1012-121 Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: Results from the carvedilol or metoprolol European trial (COMET) (2004) (2)
- Medical Misinformation: Vet the Message! (2019) (2)
- Early administration of ramipril in acute myocardial infarction: neurohormonal and hemodynamic effects and tolerability. (1997) (2)
- Medical misinformation: vet the message! (2019) (2)
- Could beta-blockers precede or replace angiotensin-converting enzyme inhibitors in heart failure? (2005) (2)
- Abstract 5066: The Treatment Effect of Perindopril is Consistent in All Patients with Vascular Disease or High Risk of Vascular Disease: A Combined Analysis of Three Perindopril Trials (2008) (2)
- DESIGN PERindopril — Function of the Endothelium in Coronary Artery Disease Trial : The PERFECT Study — Sub Study of EUROPA : Rationale and Design (2002) (2)
- Metabolic and neurohumoral aspects of acute myocardial ischemia in man (1990) (1)
- Is angina really the gold standard to test interventions in ischemia (1993) (1)
- Carvedilol treatment is as well tolerated as angiotensin converting enzyme inhibition in patients with chronic heart failure: Results of the CARMEN (Carvedilol ACE inhibitor remodeling mild CHF evaluation) study (2003) (1)
- Reconsider the management of all coronary artery disease patients: Importance of the EUROPA trial (2003) (1)
- Medical misinformation: Vet the message! (2019) (1)
- 183 Carvedilol has a better protective effect against major vascular events than metoprolol in heart failure ‐ Results from the COMET study (2004) (1)
- Medical Misinformation. (2019) (1)
- Aldosterone and Myocardial Infarction—Are Aldosterone Antagonists Needed to Prevent Remodelling or Does Ace Inhibition Suffice? (2001) (1)
- 1145-123 Inadequate perception of heart failure is associated with underuse of diagnostic and therapeutic strategies in heart failure by the primary care physician: Results from SHAPE, a major European survey (2004) (1)
- Should beta-blocker therapy be reduced or withdrawn in patients with worsening heart failure? insights from COMET (2004) (1)
- Clinical Trials Update Esc Congress 2011 (2012) (1)
- A Statement on Ethics from the HEART Group (2008) (1)
- Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure (1990) (1)
- Systemic and myocardial neurohumoral changes during ischemia in man (1987) (1)
- Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction. (1998) (1)
- 835-1 A comparison of adverse events occurring with carvedilol or metoprolol in the treatment of heart failure: Results from COMET (2004) (1)
- Acute hemodynamic and antiischemic effects of trandolapril in patients with coronary artery disease (1996) (1)
- My Last Issue—a Farewell to Cardiovascular Drugs and Therapy (2019) (1)
- Importance of atrial fibrillation in chronic heart failure in patients treated with β-blockers. results from COMET (2004) (1)
- Myocardial metabolism during pacing-induced ischemia in man. Temporal relationship with changes in post-stenotic coronary flow (1986) (1)
- Preload dependent hemodynamic improvement by the calcium sensitizer isomazole in moderate heart failure (1992) (1)
- β Blockade in congestive heart failure (1998) (1)
- Pimobendan, a novel Ca2+-sensitizer/PDE-inhibitor, improves cardiac function without tolerance to its vasodilating effects during long-term therapy in moderate CHF (1992) (1)
- Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure. (1995) (1)
- SHAPE: A Pan-European general public heart failure awareness and survey (2003) (1)
- Myocardial Ischemia: A Profile of its Pathophysiological Basis and its Detection by Nuclear Cardiology (1985) (1)
- Consistent survival benefit of carvedilol over metoprolol irrespective of baseline characteristics of heart failure patients – mode of death evaluation in COMET (2004) (1)
- 787-1 ACE Inhibition Acutely Stimulates Sympathetic Tone and Improves Myocardial Contractility and Coronary Flow in Coronary Artery Disease. A Bradykinin-related Effect? (1995) (1)
- Cardiovascular effects of aprindine, a new antiarrhythmic drug. (1975) (1)
- 1031–34 Differential Effect of Bisoprolol on Heart Rate Variability According to Heart Rate in Patients with Heart Failure (1995) (1)
- A Statement on Ethics from the HEART Group (2008) (0)
- Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease (1994) (0)
- Hemodynamic and metabolic changes caused by regional ischemia in porcine heart. (1976) (0)
- WITHDRAWN: Effects of perindopril on late cardiac remodeling in elderly patients after acute myocardial infarction: The preami echo study (2007) (0)
- 1012-103 Blood pressure changes do not influence the beneficial effects of carvedilol compared to metoprolol in the patients with heart failure: Results from COMET (carvedilol or metoprolol European trial) (2004) (0)
- Beta-blockade and coronary hemodynamics (1995) (0)
- Medical Misinformation. (2019) (0)
- Heart failure in Asia (2008) (0)
- A statement on ethics from the HEART group (2008) (0)
- Abstracts of Communications to be Presented at 11th International Congress on Cardiovascular Pharmacotheraphy, Montreal, QC, Canada 18–21 May 2002 (2002) (0)
- Do Standardized Beta-Blocker Titration Protocols in Heart Failure Improve Compliance? The GESICA Registry Experience (2005) (0)
- Pharmacological intervention in the beta-adrenergic systems in heart failure : Are all beta-blockers the same? (2002) (0)
- Medical misinformation: vet the message! (2019) (0)
- A new treatment option for severe heart failure (2000) (0)
- A Statement on Ethics from the HEART Group (2010) (0)
- Normalization of cardiac catecholamine balance during ischemia by enalaprilat epiphenomenon or basis for its antiischemic properties (1991) (0)
- Randomized trial with intracoronary streptokinase versus placebo (The Netherlands) (1986) (0)
- From the Editor (2004) (0)
- in patients with congestive heart failure Hemodynamic and neurohumoral effects of continuous infusion of levosimendan (2011) (0)
- Future of β-blocking therapy in congestive heart failure (1998) (0)
- Acute antiischemic effect of chronic beta-blocking therapy is affected by different dosage schemes. Sustained release form compared with normal galenic metoprolol (1992) (0)
- 523 Inadequate awareness and perception of heart failure by European general practitioners leads to underuse of guideline‐recommended diagnostic and therapeutic strategies — SHAPE results (2004) (0)
- Ace inhibition with perindopril and markers of atherosclerosis and thrombosis: Results of the pertinent study (2007) (0)
- Prognostic significance and the evolution of renal insufficiency in COMET trial (2004) (0)
- Does chronic beta-blockade modulate ischemia-induced hemodynamic and neurohumoral changes in patients with coronary artery disease? (1992) (0)
- Hemodynamic and neurohumoral effects of 24-hour infusion of levosimendan in patients with heart failure (1999) (0)
- Medical Misinformation: Vet the Message! (2019) (0)
- Medical Misinformation. (2019) (0)
- 188 Incidence and type of adverse events occurring with carvedilol or metoprolol in the treatment of heart failure; results from COMET (2004) (0)
- Myocardial hypoxanthine release: A better marker of myocardial ischemia? (1978) (0)
- Pathophysiology and therapy of heart failure, new insights and developments. Part I. (1992) (0)
- Evidence-based medicine in heart failure : towards better treatment : the proceedings of the task force of the working group on heart failure of the european society of cardiology, Cologne, Germany, 26 May 1997 (1998) (0)
- Is monotherapy with ACE inhibition preferable to diuretics in mild heart failure? A comparison of benazepril and hydrochlorothiazide (1996) (0)
- Contents, Vol. 88, 1997 (1997) (0)
- New insight into neurohormonal blockage (2008) (0)
- A New Editorial Office (2004) (0)
- Abstract 2456: Strong and Independent Association between Angiotensinogen Gene Polymorphisms and Hypertension in 10060 Patients with Stable Coronary Artery Disease (2008) (0)
- Changes in purine nucleoside content in human myocardial efflux during pacing-induced ischemia. (1976) (0)
- Silentischemia. Is cardiac renin-angiotensin involved? (1991) (0)
- Carmoxirole, a novel selective DA2-receptor agonist, acutely reduces neurohormonal activation and improves cardiac function in moderate to severe heart failure (1996) (0)
- From the Editor – A New Editorial Board and a New Approach (2007) (0)
- Review policy for supplements (2004) (0)
- 458 Poor treatment of patients with heart failure: lack of knowledge of current guidelines by cardiologists or too few patients treated by cardiologists? Results of SHAPE (2005) (0)
- 151 Predischarge echo-Doppler predictors of late cardiac remodeling in the placebo arm of the PREAMI Echo Study (2006) (0)
- How to treat diastolic heart failure: a personal point of view. (1999) (0)
- Medical Misinformation. (2019) (0)
- Subject Index Vol. 88,1997 (1997) (0)
- [PP.13.01] THE TREATMENT BENEFIT OF THE ACE-INHIBITOR PERINDOPRIL ON TOP OF BETA-BLOCKER THERAPY IN PATIENTS WITH VASCULAR DISEASE (2016) (0)
- Congestive heart failure. Drug therapy: central or peripheral approach? (1993) (0)
- 931-108 Parasympathetic Intervention Affects Ischemia by Increasing Coronary Flow in Normal, but not in Impaired Left Ventricular Function. A New Approach to Antiischemic Therapy? (1995) (0)
- Advances in the treatment of heart failure : therapeutic targets for a new millennium : proceedings of a symposium held at the XVIIIth Congress of the European Society of Cardiology, Birmingham, U.K., August 1996 (1998) (0)
- Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure (1996) (0)
- Modulation of the renin-angiotensin-aldosterone system – pivotal in heart failure treatment (1999) (0)
- Hypoxanthine and lactate release and intracoronary distribution changes of krypton-81M during myocardial ischemia in man (1985) (0)
- Female gender does not impact outcomes in patients with postinfarct left ventricular dysfunction treated with carvedilol (2002) (0)
- Medical Misinformation. (2019) (0)
- Myocardial perfusion and krypton-81m (1992) (0)
- Medical Misinformation - Vet the Message! (2019) (0)
- Medical Misinformation. (2019) (0)
- Medical misinformation: vet the message! (2019) (0)
- Evidence-based medicine in heart failure: towards better treatment. Introduction. (1998) (0)
- WITHDRAWN: Predischarge echo-doppler predictors of late cardiac remodeling in the placebo arm of the preami echo study (2007) (0)
- Analysis of Heart Rate Variability may Predict Efficacy of Metoprolol in the Treatment of Myocardial Ischemia During Daily Life (2013) (0)
- Cardiovascular Drugs and Therapy Celebrates its 30th Year with the Appointment of a New Co-Editor-in-Chief (2016) (0)
- 179 Comparison of the effects of metoprolol and Carvedilol on symptoms, well‐being and quality‐adjusted life‐years: a description of the “patient‐journey” in COMET (2004) (0)
- First Global Conference on Cardiovascular Clinical Trials and Pharmacotherapy Abstracts (2004) (0)
- Abstracts of Papers to be presented at the 8th International Symposium on Cardiovascular Pharmacotherapy, Amsterdam, THE NETHERLANDS, March 28–April 1, 1999 (1999) (0)
- Differential anti-ischaemic effects of muscarinic receptor blockade in patients with obstructive coronary artery disease; impaired vs normal left ventricular function. (1999) (0)
- Initial clinical experience with the cancion ™ cardiac recovery system (2003) (0)
- Congestive heart failure II (2004) (0)
- Does cardiac remodeling after myocardial infarction differ in the elderly (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Willem J. Remme?
Willem J. Remme is affiliated with the following schools:
